Tests a new dialysis filter on symptoms in adults with kidney failure
Compares a new dialyzer with the current one for symptoms in adults on dialysis.
Plain-language title generated from the registry record
Registry title: An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
Key facts
- Where
- Halifax, London, and Winnipeg, CanadaSee the 4 sites
Where in Canada
- QEII Health Sciences Centre, Nova Scotia HealthHalifax, CanadaTaking people
- Victoria Hospital, London Health Sciences CentreLondon, CanadaTaking people
- Westmount Kidney Care CentreLondon, CanadaTaking people
- Seven Oaks Hospital Chronic Disease Innovation Centre Inc. (CDIC)Winnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT06032208
- Record updated
- 4 May 2026
- Original description
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.Read full original descriptionShow less
An Extension of an Interventional Study to Assess the Effect of Expanded Dialysis (HDx-Theranova) on Patient Reported Symptoms Using London Evaluation of Illness (LEVIL)
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness "LEVIL," an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.
Inclusion: Conventional thrice weekly HD schedule; Must be on chronic hemodialysis for at least 3 months; Age ≥18 years; Willing and able to give informed consent.
Exclusion: Patients receiving daily hemodialysis treatment; Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months; Active infection (may enroll once infection is cleared); Visual impairment; History of neurocognitive impairment; History of stroke (CVA).